Halozyme Therapeutics Inc (HALO)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 367,091 | 265,865 | 256,044 | 149,680 | -60,624 |
| Long-term debt | US$ in thousands | 1,499,250 | 1,492,770 | 787,255 | 0 | 383,045 |
| Total stockholders’ equity | US$ in thousands | 83,808 | 169,798 | 196,953 | 151,047 | 91,765 |
| Return on total capital | 23.19% | 15.99% | 26.02% | 99.09% | -12.77% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $367,091K ÷ ($1,499,250K + $83,808K)
= 23.19%
Halozyme Therapeutics Inc.'s return on total capital has exhibited volatility over the last five years. The company's return on total capital was 21.32% in 2023, showing an improvement compared to the previous year's 15.96%. However, this return was lower than the 25.70% recorded in 2021 and 26.31% in 2020.
In 2019, Halozyme Therapeutics Inc. had a negative return on total capital of -13.68%, indicating that the company experienced challenges in generating returns from its total capital that year.
Overall, the company's return on total capital has shown fluctuation, possibly indicating changes in the efficiency of utilizing both equity and debt to generate profits over the years. It is essential for investors and stakeholders to monitor these trends to understand the company's performance and financial health.
Peer comparison
Dec 31, 2023